Evercore ISI Boosts Envista (NYSE:NVST) Price Target to $23.00

Envista (NYSE:NVST) had its price objective upped by equities researchers at Evercore ISI from $19.00 to $23.00 in a research report issued on Wednesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Evercore ISI’s price target points to a potential upside of 11.06% from the company’s previous close.

Several other brokerages have also recently weighed in on NVST. UBS Group reduced their price objective on shares of Envista from $21.00 to $18.00 and set a “neutral” rating on the stock in a research note on Monday, May 5th. Bank of America reduced their price objective on shares of Envista from $26.00 to $23.00 and set a “buy” rating on the stock in a research note on Tuesday, April 29th. Robert W. Baird raised shares of Envista from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $21.00 to $23.00 in a research note on Tuesday, May 27th. Baird R W raised shares of Envista from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 27th. Finally, Morgan Stanley set a $16.00 price objective on shares of Envista in a research note on Tuesday, April 15th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Envista currently has a consensus rating of “Hold” and a consensus target price of $20.23.

Envista Stock Performance

NYSE NVST opened at $20.71 on Wednesday. The firm’s fifty day moving average price is $18.58 and its two-hundred day moving average price is $18.51. The stock has a market cap of $3.51 billion, a PE ratio of -3.17, a PEG ratio of 1.30 and a beta of 1.00. Envista has a fifty-two week low of $14.22 and a fifty-two week high of $23.00. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.82 and a current ratio of 2.12.

Envista (NYSE:NVST) last posted its earnings results on Thursday, May 1st. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.20 by $0.04. The firm had revenue of $616.90 million for the quarter, compared to analysts’ expectations of $608.17 million. Envista had a negative net margin of 44.90% and a positive return on equity of 4.07%. The company’s revenue was down 1.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.26 earnings per share. On average, equities analysts expect that Envista will post 1 EPS for the current fiscal year.

Hedge Funds Weigh In On Envista

Several hedge funds have recently modified their holdings of NVST. UMB Bank n.a. lifted its position in shares of Envista by 214.4% during the 1st quarter. UMB Bank n.a. now owns 2,094 shares of the company’s stock worth $36,000 after buying an additional 1,428 shares in the last quarter. Parallel Advisors LLC lifted its position in shares of Envista by 100.1% during the 2nd quarter. Parallel Advisors LLC now owns 2,792 shares of the company’s stock worth $55,000 after buying an additional 1,397 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp bought a new position in shares of Envista during the 4th quarter worth approximately $86,000. Palouse Capital Management Inc. lifted its position in shares of Envista by 14.4% during the 1st quarter. Palouse Capital Management Inc. now owns 9,444 shares of the company’s stock worth $163,000 after buying an additional 1,186 shares in the last quarter. Finally, FourThought Financial Partners LLC purchased a new stake in shares of Envista during the 1st quarter worth approximately $180,000.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.